Susquehanna International Group, LLP Adial Pharmaceuticals, Inc. Transaction History

Susquehanna International Group, LLP

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 11, 2023	SELL	$0.21 - $0.37 $8,819 - $15,539	-41,998 Reduced 18.89%	180,285 $37,000
Q1 2023 May 16, 2023	BUY	$0.24 - $0.56 $31,508 - $73,520	131,287 Added 144.28%	222,283 $77,000
Q4 2022 Feb 14, 2023	BUY	$0.2 - $0.31 $18,199 - $28,208	90,996 New	90,996 $20,000
Q2 2022 Aug 15, 2022	BUY	N/A	80,986 Added 447.02%	99,103 $133,000
Q1 2022 May 16, 2022	BUY	N/A	5,925 Added 48.6%	18,117 $36,000

Q4 2021 Feb 14, 2022	BUY	N/A	12,192 New	12,192 $33,000
Q2 2020 Aug 14, 2020	SELL	N/A	-13,714 Closed	0 $0
Q1 2020 May 15, 2020	BUY	N/A	13,714 New	13,714 $18,000

5.5K

Ticker ADIL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 26,854,000
Market Cap $28.2M
Description
Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead product is AD04, a selective serotonin-3 antagonist, which is in Phase III clinical trial for the treatment of alcohol use disorder. The company also focu...

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

Stay updated on Susquehanna International Group, LLP with notifications on news.